Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Question About HAART Quad Therapy
Jul 10, 2012

After consultation with a specialist, the following specific HARRT regime was drawn up:

Abacavir 600mg once daily Lamivudine 300mg once daily Lopinavir 400mg twice daily Ritonavir 100mg twice daily

What three types of patients is this treatment regime designed for?

Response from Dr. Young

Hello and thanks for posting.

I'm not sure about three types of patients, but a regimen of two NRTIs (abacavir and lamivudine) and a ritonavir-boosted protease inhibitor (lopinavir, aka, Kaletra) could be used for first-line patients or for patients with prior treatment experience (either for switching treatment or drug resistance).

If your not sure why your HIV provider has selected this regimen, it's worth a conversation.

BY



Previous
Time guidelines for PEP
Next
Efficacy/Synergy of Isentress+Norvir+Prezista+Viread

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement